



Pharmacy Request for Prior Approval – Growth Hormone (Children Less than 21 Years of Age)

Beneficiary Information

1. Beneficiary Last Name: 2. First Name: 3. Beneficiary ID #: 4. Beneficiary Date of Birth: 5. Beneficiary Gender:

Prescriber Information

6. Prescriber Name: NPI #: Mailing address: City: State: ZIP: 7. Requester Contact Information: Name: Phone #: Fax #:

Drug Information

8. Drug Name: 9. Strength: 10. Quantity Per 30 Days: 11. Length of Therapy: up to 30 days 60 days 90 days 120 days 180 days 365 days Other:

Clinical Information

1. Diagnosis: For NON-PREFERRED DRUGS (complete this section as well as below): 2. Failed two preferred drugs. List preferred drugs failed: Or list reason why patient cannot try two preferred drugs: 3. History of: Turners Syndrome Prader Willi Syndrome Craniopharyngioma in the last 2 years Panhypopituitarism in the last 2 years Cranial Irradiation in the last 2 years MRI History of Hypopituitarism - List: Hypopituitarism Chronic Renal Insufficiency in the last 2 years SGA with IUGR Other: 4. Please check all that apply: Patient has a height velocity <25th percentile for Bone Age Height Velocity: Patient has low serum levels of IGF-1 and IGFBP-3 IGF-1 Level: IGFBP-3 Level: Patient has other signs of hypopituitarism List: Patient is an adequately nourished child with hypoglycemia and a low GH response to hypoglycemia Patient's height is < 3rd percentile for chronological age Height: Weight: Birth weight and/or length more than 2 standard deviations below mean for gestational age with no catch up by age 2. History of GHD in the last 2 years. Is there a genetic cause? Stim testing? Agent 1: Agent 2: Peak: Ng/ml: 5. Is the epiphysis open (if patient > 9 years old)? Yes No 6. Is the patient diagnosed with unexplained short stature with height > 2.25 standard deviations below mean for age, and bone age > 2 standard deviations below mean, and low serum levels of IGF-1 and IGFBP-3? Yes No IGF-1 Level: IFG-BP3 Level: 7. Is the patient currently being treated? Yes No 7a. Growth rate over previous year: 7b. Has the patient entered puberty? Yes No 8. Are IGF-1 and IGF-BP3 within age appropriate range? Yes No Results: Zorbitive only: 9. Is there a history of short bowel syndrome in the last 2 years? Yes No Increlex only: 10. Check all that apply: History of GH product in last year GH resistance is caused by mutation in GH receptor of post GH receptor signaling pathway Patient has IGF-1 gene defects GH gene deletions and patient has developed neutralizing antibodies to GH Patient height < 3 SD < mean and IGF-1 level < 3 SD < mean and normal or elevated GH levels.

Signature of Prescriber: Date:

\*Prescriber signature mandatory

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.